Filtered By:
Condition: Thrombosis
Procedure: Heart Valve Surgery

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 230 results found since Jan 2013.

Impact of mitral versus aortic bioprosthetic valve position  on thromboembolism and bleeding risk in patients with atrial fibrillation
CONCLUSIONS: In Japanese patients with AF and bioprosthetic valves, thromboembolic risk does not differ on the basis of valve position. Bleeding risk is higher in patients with MV bioprostheses, although valve position itself might not be an independent predictor for bleeding.PMID:34716054 | DOI:10.1016/j.jjcc.2021.10.002
Source: Journal of Cardiology - October 30, 2021 Category: Cardiology Authors: Yuki Obayashi Makoto Miyake Masashi Amano Takeshi Kitai Misa Takegami Kunihiro Nishimura Toshihiro Tamura Yutaka Furukawa Chisato Izumi Source Type: research

New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Risk of Stroke After Transcatheter Aortic Valve Implantation: Epidemiology, Mechanism, and Management
Conclusions: The overall evidences confirm similar or lower rate of stroke in TAVI versus SAVR. Risk predictors for acute stroke after TAVI are generally related to procedural factors, whereas late stroke is mainly associated with patient characteristics, with a variable impact on cognitive function. The optimal choice for the antithrombotic treatment in TAVI for stroke prevention is yet to be determined. Current data do not support routine use of cerebral embolic protection devices during TAVI.
Source: American Journal of Therapeutics - September 1, 2021 Category: Drugs & Pharmacology Tags: Therapeutic Advances Source Type: research

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Outcomes related to anticoagulation management for mechanical valve replacements
CONCLUSIONS: Taking into account relevant comorbidities and valve type, patients with a larger proportion of non-therapeutic INRs during the first post-operative year demonstrated no difference in longitudinal clinical outcomes. Further research into more standardized INR monitoring and potentially expanded INR target ranges for patients undergoing mechanical valve replacement is warranted.PMID:34164179 | PMC:PMC8182532 | DOI:10.21037/jtd-20-2562
Source: Journal of Thoracic Disease - June 24, 2021 Category: Respiratory Medicine Authors: Lauren V Huckaby Laura M Seese Thomas G Gleason Ibrahim Sultan Yisi Wang Floyd Thoma Arman Kilic Source Type: research